Does an antithrombotic regimen including apixaban without aspirin reduce bleeding and hospitalizations in patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor?
In patients with atrial fibrillation and recent ACS or PCI, an apixaban-based regimen without aspirin reduces bleeding and hospitalizations compared to VKA and/or aspirin without increasing ischemic risk.
In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).
Lópes et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: